DSGN

• U.S. Stock Market Performance: U.S. stocks rose, with the Dow Jones increasing by over 250 points, driven by strong earnings reports from several companies.

• Nutex Health Inc Surge: Nutex Health's shares jumped 37.3% after reporting quarterly sales of $267.804 million, significantly exceeding market expectations.

• Other Notable Stock Gains: PACS Group, Cerence Inc, and Exact Sciences Corp also saw substantial increases in their stock prices following positive financial results and forecasts.

• Walmart's Positive Outlook: Walmart's shares rose 6.5% after reporting strong third-quarter results and raising its revenue and earnings outlook for FY26, along with plans to transfer its listing to Nasdaq.

Steven Cohen's Biotech Investments

• Point72 Asset Management's New Stakes: Billionaire hedge fund manager Steven Cohen is making significant investments in small-cap biotech firms, particularly focusing on companies with promising genetic and antibody therapies. His firm has recently acquired stakes in Invivyd Inc. and Design Therapeutics Inc., capitalizing on their recent stock performance.

• Invivyd Inc. Investment: Point72 disclosed a new position in Invivyd, purchasing 16.73 million shares for $17.23 million at an average price of $1.03. Invivyd's stock has surged 106% year-to-date, with a notable 22% increase in the past month. Despite being below its 52-week high of $2.74, the stock has rebounded from a low of 35 cents, driven by optimism surrounding its monoclonal antibody candidate VYD222.

• Design Therapeutics Stake Increase: Cohen's firm increased its stake in Design Therapeutics by 62.8%, acquiring an additional 1.14 million shares. The current stake is valued at approximately $5.64 per share, reflecting a 24% increase from the initial entry price of $4.55. Design Therapeutics has seen its shares rise nearly 42% in the past month and 19.8% over the past year, with its GeneTACTM molecules targeting specific genetic diseases.

Market Trends and Future Outlook

• Growing Hedge Fund Interest: Cohen's investments highlight a broader trend of hedge funds seeking high-risk, high-reward opportunities in the biotech sector. The market response to small-cap biotech stocks indicates a growing appetite for innovative therapies, particularly as these companies show potential for significant breakthroughs.

• Performance of Other Biotech Stocks: Alongside Invivyd and Design Therapeutics, Cohen has also invested in Structure Therapeutics and Entrada, which are gaining traction in the market. The performance of these stocks in 2025 suggests that investors are increasingly optimistic about the future of small-cap biotech investments.